RxDoctor Payments Data

Niralee Patel

Nephrology · Cincinnati, OHNPI 1053721654

Payments from drug & device makers

$3,116in general payments, 2019–2025

Across 34 payments — averaging $91.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$691
  • AstraZeneca$504
  • Amgen$471
  • Nxstage Medical, Inc.$395
  • Calliditas Therapeutics US Inc.$325
  • Mallinckrodt Hospital Products Inc.$179
  • plus $552 from 6 others

What the payments were for

  • Food & beverage$2,93794%
  • Education$1796%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,116 in reported general payments places this provider in the 65th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$67,086
Medicare patients
179
Services billed
759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide16$25,280
LokelmaSodium Zirconium Cyclosilicate13$14,908
Valganciclovir Hcl18$11,566
EliquisApixaban12$10,342
Cinacalcet Hcl38$3,003
Tacrolimus28$2,788
Nifedipine ErNifedipine73$2,552
Mycophenolate Mofetil21$2,385
Potassium Citrate ErPotassium Citrate16$794
Carvedilol110$664
Calcitriol22$430
Famotidine63$370
Pantoprazole Sodium37$360
Tamsulosin Hcl21$320
Omeprazole19$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$504$14,90813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 450 nephrology providers in Ohio.

Other nephrology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →